Asia
B&K Corporation Enrolls Patient in Phase 3a Clinical Trial of Burns Drug
B&K Corporation (HKG:2396) said it enrolled the first patient in the phase 3a clinical trial of Pro-101-1 to treat deep second-degree burns, according to a Tuesday filing with the Hong Kong bourse.The biopharmaceutical company shares fell 1% in morning trade Wednesday.Pro-101-1 is one of the core products of the company.
HKG:2396
